Coave Therapeutics Secures $33M Series A Financing to Advance Next-Generation Gene Therapies

Jan 13, 2025 10:50 CST Updated 10:50

Coave Therapeutics

Developer of Gene Therapies for Ophthalmic and Central Nervous System Diseases

Novo Holdings

Venture Capital and Asset Management Firms

Bpifrance

Financial Services Institutions

Invus

Equity Investment Firms

UI Investissement

Private Equity Investment Firms

Seroba Life Sciences

Life Sciences Venture Capital Firm

Fund+

Open-end Fund

Kurma Partners

Healthcare-Focused Venture Capital Firms

Omnes Capital

Private Equity Investment Firm

Turenne Capital

An Independent Private Equity Management Firm

January 9,Coave Therapeutics ("Coave"), a company pioneering the future of genetic medicines in Paris, France, announced the completion of a €32 million (US$33 million) Series A financing round. The financing was co-led by Novo Holdings A/S and Bpifrance Portfolio Companies, with participation from Invus, UI Investment, and existing investors Seroba Life Sciences, Fund+, Kurma Partners, Omnes Capital, and Turenne Capital.

This financing will enableCoaveCapable of advancing its proprietary ALIGATER™ (Advanced Ligand-Guided AAV and Non-Viral Vectors) platform, a breakthrough technology that addresses the key limitations in delivering genetic payloads to extrahepatic tissues, including limited tissue specificity, delivery efficiency, and safety. ALIGATER™ enables the conjugation of targeting ligands (such as small molecules, peptides, or antibody fragments) to AAV or non-viral vectors, providing superior delivery efficiency, tissue specificity, and safety for a range of diseases. Importantly, the platform simplifies the manufacturing process by avoiding previous AAV capsid modifications. These capabilities will enable Coave Therapeutics to develop first-in-class gene therapies tailored to specific indications.

This funding will also enable Coave to advance its leading preclinical assets into clinical development, primarily focusing on central nervous system (CNS), neuromuscular, and ocular diseases. Coave plans to advance two development candidate pipelines to CTA/IND for research by 2026.

Coave Therapeutics CEO Rodolphe Clerval stated:"We are delighted to welcome this group of top investors to share our vision for the ALIGATER™ platform. This funding represents a significant milestone for Coave Therapeutics in developing a new generation of targeted, safer, and more effective gene therapies. It also strengthens our ability to expand collaborations with pharmaceutical and biotech partners, driving innovation in the field of genetic medicines for the treatment of various diseases."

Emmanuelle Coutanceau, Partner at Novo Holdings Seed Investments, stated:"Coave's unique technology platform, robust proof-of-concept data, and experienced team position them as a leader in developing the next generation of gene therapies. We are thrilled to see Coave acquire one of our stealth-mode companies, expanding their international presence in Denmark."

Follow the official account below to see the world!